PROHIBITION OF SALES TO EEA RETAIL INVESTORS – The Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area ("**EEA**"). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, "**EU MiFID II**"); (ii) a customer within the meaning of Directive (EU) 2016/97 (the "**Insurance Distribution Directive**"), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of EU MiFID II; or (iii) not a qualified investor as defined in the Prospectus Regulation. Consequently no key information document required by Regulation (EU) No 1286/2014 (the "**PRIIPs Regulation**") for offering or selling the Notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation.

PROHIBITION OF SALES TO UK RETAIL INVESTORS – The Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the United Kingdom ("UK"). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client, as defined in point (8) of Article 2 of Regulation (EU) No 2017/565 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("EUWA"); (ii) a customer within the meaning of the provisions of the FSMA and any rules or regulations made under the Financial Services and Markets Act 2000 (the "FSMA") to implement Directive (EU) 2016/97, where that customer would not qualify as a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the EUWA; or (iii) not a qualified investor as defined in Article 2 of the UK Prospectus Regulation. Consequently no key information document required by Regulation (EU) No 1286/2014 as it forms part of domestic law by virtue of the EUWA (the "UK PRIIPs Regulation") for offering or selling the Notes or otherwise making them available to any retail investor in the UK may be unlawful under the UK PRIIPs Regulation.

EU MIFID II product governance / Professional investors and ECPs only target market – Solely for the purposes of each manufacturer's product approval process, the target market assessment in respect of the Notes has led to the conclusion that: (i) the target market for the Notes is eligible counterparties and professional clients only, each as defined in EU MiFID II; and (ii) all channels for distribution of the Notes to eligible counterparties and professional clients are appropriate. Any person subsequently offering, selling or recommending the Notes (a "distributor") should take into consideration the manufacturers' target market assessment; however, a distributor subject to EU MiFID II is responsible for undertaking its own target market assessment in respect of the Notes (by either adopting or refining the manufacturers' target market assessment) and determining appropriate distribution channels.

Coloplast Finance B.V. Legal entity Identifier (LEI): 529900WUKMUUP16A4F62

Issue of EUR 700,000,000 2.750 per cent. Notes due 19 May 2030

unconditionally and irrevocably guaranteed by Coloplast A/S Legal entity Identifier (LEI): 529900NN7SOJ5QG82X67

under the EUR 3,500,000,000 Euro Medium Term Note Programme

PART A – CONTRACTUAL TERMS

Terms used herein shall be deemed to be defined as such for the purposes of the Conditions (the "**Conditions**") set forth in the Base Prospectus dated 9 May 2022 which constitutes a base prospectus (the "**Base Prospectus**") for the purposes of the Prospectus Regulation. This document constitutes the Final Terms of the Notes described herein for the purposes of the Prospectus Regulation and must be read in conjunction with the Base Prospectus in order to obtain all the relevant information.

The Base Prospectus has been published on 9 May 2022.

The expression "**Prospectus Regulation**" means Regulation (EU) 2017/1129 and the expression "**UK Prospectus Regulation**" means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the EUWA.

1.	(i)	Issuer:	Coloplast Finance B.V.
	(ii)	Guarantor:	Coloplast A/S
2.	(i)	Series Number:	3
	(ii)	Tranche Number:	1
	(iii) Date on which the Notes become fungible:		Not Applicable
3.	Specifi Curren	ed Currency or cies:	Euro (" EUR ")
4.	Aggreg	ate Nominal Amount:	
	(i)	Series:	EUR 700,000,000
	(ii)	Tranche:	EUR 700,000,000
5.	Issue P	rice:	99.950 per cent. of the Aggregate Nominal Amount
6.	(i) Specified Denominations:		EUR 100,000 and integral multiples of EUR 1,000 in excess thereof up to and including EUR 199,000. No Notes in definitive form will be issued with a denomination above EUR 199,000.
	(ii)	Calculation Amount:	EUR 1,000
7.	(i)	Issue Date:	19 May 2022
	(ii) Int Da	terest Commencement te:	Issue Date
8.	Maturit	ty Date:	19 May 2030
9.	Interest Basis:		2.750 per cent. Fixed Rate
			(see paragraph 14 below)
10.	Redem	ption/Payment Basis:	Subject to any purchase and cancellation or early redemption, the Notes will be redeemed on the Maturity Date at 100.00 per cent. of their nominal amount.

11.	Change of Interest or Redemption/Payment Basis:		Not Applicable
-		Options:	Change of Control Put Option
			Issuer Call
			Issuer Residual Call – Applicable
			(see paragraphs 17, 19 and 20 below)
13.	(i)	Status of the Notes:	Senior
	(ii)	Status of the Guarantee of the Notes:	Senior
	(iii)	Date Board approval for issuance of Notes and Guarantee of the Notes (respectively) obtained	Both 25 April 2022
PROVIS	IONS RI	ELATING TO INTERES	T (IF ANY) PAYABLE

14. **Fixed Rate Note Provisions** Applicable

(i)	Rate of Interest:	2.750 per cent. per annum payable annually in arrear on each Interest Payment Date
(ii)	Interest Payment Date(s):	19 May in each year from and including 19 May 2023 to and including the Maturity Date
(iii)	Fixed Coupon Amount:	EUR 27.50 per Calculation Amount
(iv)	Fixed Coupon Amount for a short or long Interest Period ("Broken Amount(s)")	Not Applicable
(v)	Day Count Fraction:	Actual/Actual (ICMA)
Floati	ng Rate Note Provisions	Not Applicable
Zero Coupon Note Provisions		Not Applicable

PROVISIONS RELATING TO REDEMPTION

Call Option			Applicable
(i)	Optio Date(-	Any date from but excluding the Issue Date to but excluding the Maturity Date
(ii)	Optio Amou each I	unt(s) (Call) o	
			EUR 1,000 per Calculation Amount in respect of any Optional Redemption Date from and including the Par Redemption Date to but excluding the Maturity Date.
(iii)	Make Redei	Whol Whol	e Non-Sterling Make Whole Redemption Amount
	(a)	Reference Bond	DBR 0% due February 2030 (ISIN: DE0001102499)
	(b)	Quotation Time:	11.00 am CET
	(c)	Redemption Margin:	0.300 per cent.
	(d)	Par Redemption Date:	n 19 February 2030
(iii)	Rede	mption in part:	Not Applicable

15. 16.

17.

	(iv)	Notice period:	As per the Conditions
18.	Put Option		Not Applicable
19.	Issuer Residual Call		Applicable
	(i)	Notice period:	Minimum period: As per the Conditions
			Maximum period: As per the Conditions
	(ii)	Optional Redemption Amount (Residual Call):	EUR 1,000 per Calculation Amount
20.	Change of Control Put Option:		Applicable
21.	Final Redemption Amount of each Note		EUR 1,000 per Calculation Amount
22.	Early Redemption Amount		
	Early Redemption Amount(s) per Calculation Amount payable on redemption for taxation reasons or other early redemption:		EUR 1,000 per Calculation Amount
23.	Early T	ermination Amount:	EUR 1,000 per Calculation Amount

GENERAL PROVISIONS APPLICABLE TO THE NOTES

24.	Form of Notes:	Bearer Notes:	
		Temporary Global Note exchangeable for a Permanent Global Note which is exchangeable for Definitive Notes in the limited circumstances specified in the Permanent Global Note	
25.	New Global Note:	Yes	
26.	Additional Financial Centre(s) or other special provisions relating to payment dates:	Not Applicable	
27.	Talons for future Coupons to be attached to Definitive Notes (and dates on which such Talons mature):	No	

Signed on behalf of Coloplast Finance B.V.

By: /s/ Henrik Deneke Duly authorised

By: /s/ Anton Mikkelsen Duly authorised

Signed on behalf of Coloplast A/S

By: /s/ Kristian Villumsen Duly authorised By: /s/ Anders Lonning-Skovgaard Duly authorised

PART B – OTHER INFORMATION

LISTING AND ADMISSION 1. TO TRADING

(i)	Admission to Trading:	Application is expected to be made by the Issuer (or on its behalf) for the Notes to be admitted to trading on the regulated market of Nasdaq Copenhagen A/S with effect from the Issue Date.

(ii) Estimate of total EUR 5,000 expenses related to admission to trading:

RATINGS The Notes to be issued are expected to be rated:

Ratings:

2.

Standard & Poor's Global Ratings Europe Limited ("S&P"): BBB

An obligation rated 'BBB' exhibits adequate protection parameters. However, adverse economic conditions or changing circumstances are more likely to weaken the obligor's capacity to meet its financial commitments on the obligation (source: https://www.maalot.co.il/Publications/GMT20160823145849.p df)

S&P is established in the EEA and registered under Regulation (EU) No 1060/2009, as amended (the "EU CRA Regulation"). S&P appears on the latest update of the list of registered credit rating agencies (as of 24 March 2022) on the ESMA website http://www.esma.europa.eu.

Eurosystem either upon issue or at any or all times during their

INTERESTS OF NATURAL AND LEGAL PERSONS INVOLVED IN THE ISSUE/OFFER 3.

The net proceeds from the issue of the Notes will be used to repay certain indebtedness of the Guarantor provided by the Dealers, see paragraph 6. (Reasons for the Offer and Estimated Net Amount of Proceeds) below. Save for such use of proceeds and any fees payable to the Dealers, so far as the Issuer and the Guarantor are aware, no person involved in the offer of the Notes has an interest material to the offer. The Dealers and their affiliates have engaged, and may in the future engage, in investment banking and/or commercial banking transactions with, and may perform other services for, the Issuer and the Guarantor and their affiliates in the ordinary course of business.

4. **YIELD**

5.

Indication of yield:	2.757 per cent. per annum	
	The yield is calculated at the Issue Date on the basis of the Issue Price. It is not an indication of future yield.	
OPERATIONAL INFORMATI	ON	
ISIN:	XS2481288525	
Common Code:	248128852	
Delivery:	Delivery against payment	
Names and addresses of additional Paying Agent(s) (if any):	Not Applicable	
Relevant Benchmark:	Not Applicable	
Intended to be held in a manner which would allow Eurosystem eligibility:	Yes. Note that the designation "yes" simply means that the Notes are intended upon issue to be deposited with one of the ICSDs as common safekeeper and does not necessarily mean that the Notes will be recognised as eligible collateral for Eurosystem monetary policy and intra day credit operations by the	

life. Such recognition will depend upon the ECB being satisfied that Eurosystem eligibility criteria have been met.

6. **DISTRIBUTION**

(i)	Method of Distribution:	Syndicated
		Syndicated
(ii)	If syndicated:	
(A)	Names of Dealers:	Joint Lead Managers
		Danske Bank A/S
		HSBC Continental Europe
		Nordea Bank Abp
		Jyske Bank A/S
		Nykredit Bank A/S
(B) St ar	abilisation Manager(s), if y:	Danske Bank A/S
	non-syndicated, name of ealer:	Not Applicable
(iv) U.	S. Selling Restrictions:	Reg S Compliance Category 2; TEFRA D
(v) EEA R	Prohibition of Sales to etail Investors:	Applicable
(vi) UK Re	Prohibition of Sales to tail Investors:	Applicable
AND	ONS FOR THE OFFER ESTIMATED NET JNT OF PROCEEDS	
Reason	ns for the offer:	Refinancing of the amounts borrowed under the EUR 3bn Facility Agreement dated 8 November 2021 entered into by Coloplast A/S to finance the acquisition of Atos Medical; any additional net proceeds to be used for general corporate purposes

Estimated net proceeds: EUR 697,319,000

7.